Skip to main content
Article
Efalizumab, a Human Monoclonal Anti-CD11a Antibody, in the Treatment of Moderate to Severe Crohn’s Disease: An Open-Label Pilot Study
Digestive Diseases and Sciences (2011)
  • Dustin G. James, Washington University in St. Louis
  • Da Hea Seo, Washington University in St. Louis
  • Jiajing Chen, Washington University in St. Louis
  • Caroline Vemulapalli, Washington University in St. Louis
  • Christian D. Stone, University of Nevada, Reno
  • Christian D. Stone, Washington University in St. Louis
Publication Date
June 1, 2011
DOI
10.1007/S10620-010-1525-6
Citation Information
Dustin G. James, Da Hea Seo, Jiajing Chen, Caroline Vemulapalli, et al.. "Efalizumab, a Human Monoclonal Anti-CD11a Antibody, in the Treatment of Moderate to Severe Crohn’s Disease: An Open-Label Pilot Study" Digestive Diseases and Sciences Vol. 56 Iss. 6 (2011) p. 1806 - 1810
Available at: http://works.bepress.com/christian-stone/21/